Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate

Abstract Background The introduction of novel hormonal therapies represented by enzalutamide (ENZ) and abiraterone acetate (ABI) has reached a great progress in the treatment of metastatic castration‐resistant prostate cancer (mCRPC). The majority of mCRPC patients are elderly suffering from chronic...

Descripció completa

Dades bibliogràfiques

Autors principals:	Ondřej Fiala, Petr Hošek, Hana Korunková, Milan Hora, Jiří Kolář, Ondřej Šorejs, Ondřej Topolčan, Jan Filipovský, Václav Liška, Matteo Santoni, Sebastiano Buti, Jindřich Fínek
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2024-01-01
Col·lecció:	Cancer Medicine
Matèries:	abiraterone acetate angiotensin‐converting enzyme inhibitors antihypertensives castration‐resistant prostate cancer comedication enzalutamide
Accés en línia:	https://doi.org/10.1002/cam4.6853
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!